


RESPONSE TO RESTRICTION REQUIREMENT

According to the Restriction Requirement, the examiner has identified two patentably distinct inventions under 35 U.S.C. § 121, as follows:

- Group I: claim(s) 1-18, drawn to the compounds, compositions process of preparing and method of use of the compounds of formula I where the bridged ring system is 3,8-diazabicyclo[3.2.1]oct-8-yl.
- Group II: claim(s) 1-18, drawn to the compounds, compositions process of preparing and method of use of the compounds of formula I where the bridged ring system is 3,7,9-triazabicyclo[3.3.1]nonane.
- Group III: claim(s) 1-18, drawn to the compounds, compositions process of preparing and method of use of the compounds of formula I where the bridged ring system is 3,8-diazabicyclo[3.2.1]oxy-3-yl.
- Group IV: claim(s) 1-18, drawn to the compounds, compositions process of preparing and method of use of the compounds of formula I where the bridged ring system is 3,9-diazabicyclo[3.3.1]non-9-yl.
- Group V: claim(s) 1-18, drawn to the compounds, compositions process of preparing and method of use of the compounds of formula I where the bridged ring system is 3-oxa-7,9-diazabicyclo[3.3.1]non-9-yl.
- Group VI: claim(s) 1-4 and 6-18, drawn to the compounds, compositions process of preparing and method of use of the compounds of formula I where the bridged ring system is 8-azabicyclo[3.2.1]oct-8-yl.
- Group VII: claim(s) 1-4 and 6-18, drawn to the compounds, compositions process of preparing and method of use of the compounds of formula I where the bridged ring system is 8-azabicyclo[3.2.1]oct-3-yl.
- Group VIII: claim(s) 1-4 and 6-18, drawn to the compounds, compositions process of preparing and method of use of the compounds of formula I where the bridged ring system is 3-oxa-7-azabicyclo[3.3.1]non-7-yl.
- Group IX: claim(s) 1-4 and 6-18, drawn to the compounds, compositions process of preparing and method of use of the compounds of formula I where the bridged ring system is 3-oxa-9-azabicyclo[3.3.1]non-9-yl.

The Restriction Requirement further includes a requirement that applicants elect a species. Applicants elect the following species (Example 109):



Applicants respectfully submit that claims 1-18 read on the elected Species.


Applicants respectfully submit that the present submission is fully responsive to the outstanding Restriction Requirement. Prompt substantive examination of all elected claims is respectfully requested.

Respectfully submitted,

Novartis Institutes for BioMedical Research, Inc.
220 Massachusetts Ave.
Cambridge, MA 02139

(617) 871-5027

Date: November 2, 2009



Agent for Applicant
Reg. No. 59,494